Natural antibiotic susceptibility of Proteus spp., with special reference to P. mirabilis and P. penneri strains

Journal of Chemotherapy

Volumn 15, Issue 1, 2003, Pages 12-26

  Stock, Ingo ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Class A lactamase; Fosfomycin; Natural antibiotic susceptibility; Natural resistance; Natural sensitivity; P. mirabilis; P. penneri

Indexed keywords

AMINOGLYCOSIDE; AMINOPENICILLIN; AMOXICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFACLOR; CEFAZOLIN; CEFOTIAM; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; FUSIDIC ACID; GLYCOPEPTIDE; LINCOSAMIDE; LORACARBEF; MACROLIDE; NITROFURANTOIN; OXACILLIN; PENICILLIN G; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOGRAMIN; SULFAMETHOXAZOLE; TETRACYCLINE; UNINDEXED DRUG; UREIDOPENICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; DATA BASE; MINIMUM INHIBITORY CONCENTRATION; PROTEUS; PROTEUS MIRABILIS; PROTEUS PENNERI; PROTEUS VULGARIS; SPECIES DIFFERENCE; VALIDATION PROCESS;

EID: 0037300782     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.1.12     Document Type: Article

References (71)

1. Wenner JJ, Rettger LF. A systematic study of the Proteus group of bacteria. J Bacteriol 1919; 4: 331-53.
2. Hauser G. [Über Fäulnisbakterien und deren Beziehungen zur Septikämie. Ein Beitrag zur Morphologie der Spaltpilze.] 1885. Vogel, Leipzig, Germany. (Article in German)
3. Cosenza BJ, Podgwaite JD. A new species of Proteus isolated from larvae of the gypsy moth Porthetria dispar (L.). Antonie van Leeuw. J Microbiol Serol 1966; 32: 187-91.
4. Hickman FW, Steigerwalt AG, Farmer JJ III, Brenner DJ. Identification of Proteus penneri sp. nov., formerly known as Proteus vulgaris indole negative or as Proteus vulgaris biogroup 1. J Clin Microbiol 1982; 15: 1097-102.
5. Brenner DJ, Hickman-Brenner FW, Holmes B, Hawkey PM, Penner JL, Grimont PAD, Mohr O'Hara C. Replacement of NCTC 4175, the current type strain of Proteus vulgaris, with ATCC 29905. Request for an opinion. Int J Syst Bacteriol 1995; 45: 870-1.
6. Mohr O'Hara C, Benner FW, Steigerwalt AG, Hill BC, Holmes B, Grimont PAD, Hawkey PM, Penner JL, Miller JM, Brenner DJ. Classification of Proteus vulgaris biogroup 3 with recognition of Proteus hauseri sp. nov., nom. rev. and unnamed Proteus genomospecies 4, 5 and 6. Int J Syst Evolut Microbiol 2000;50:1869-75.
7. Janda JM, Abbott SL, Khashe S, Probert W. Biochemical identification and characterization of DNA groups within the Proteus vulgaris complex. J Clin Microbiol 2001; 39: 1231-4.
8. Mohr O'Hara C, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev 2000; 13: 534-46.
9. Centers for Disease Control and Prevention. National nosocomial infections surveillance (NNIS) report, data summary October 1986-April 1996, issued May 1996. Am J Infect Control 1996; 24: 381.
10. Stature WE. Urinary tract infections. In: Root RK, editor. Clinical infectious diseases: a practical approach. Oxford Univeristy Press, Inc., New York, N.Y. 1999: 649-56.
11. Agro AS, Garner ET, Wright JW III, Caballeros de Escobar I, Villeda B, Seidlin M. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther 1998; 20: 744-59.
12. Obi CL, Enweani IB, Giwa JO. Bacterial agents causing chronic suppurative otitis media. Est Afr Med J 1995; 72: 370-2.
13. de Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother 2000; 45: 537-9.
14. Watanakunakorn C, Perni SC. Proteus mirabilis bacteremia: a review of 176 cases during 1980-1992. Scand J Infect Dis 1994; 26: 361-7.
15. Lam DS, Kwok AK, Chew S. Post-keratoplasty endophthalmitis caused by Proteus mirabilis. Eye 1998; 12: 139-40.
16. Chou ML, Wang HS, Huang SC, Lee N. Neonatal meningitis due to Proteus mirabilis: report of 3 cases. Changgeng Yi Xue Za Zhi 1988; 11: 66-73.
17. Grahnquist L, Lundberg B, Tullus K. Neonatal Proteus meningoencephalitis. Case report. Acta Pathol Microbiol Immunol Scand 1992; 100: 734-6.
18. Corredoira JM, Ariza J, Pallares R, Carratala J, Viladrich PF, Ruff G, Verdaguer R, Gudiol F. Gram-negative bacillary cellulitis on patients with hepatic cirrhosis. Eur J Clin Microbiol Infect Dis 1994; 13: 19-24.
19. Ananthasubramaniam K, Karthikeyan V. Aortic ring abscess and aortoatrial fistula complicating fulminant prostetic valve endocarditis due to Proteus mirabilis. J Ultrasound Med 2000; 19: 63-6.
20. Go C, Bernstein JM, de Jong AL, Sulek M, Friedman EM. Intracranial complications of acute mastoiditis. Int J Pediatr Otorhinolaryngol 2000; 52: 143-8.
21. Marx AC, Hartshorne MF, Stull MA, Truwit CL. Case report 496: intrasseous gas in Proteus mirabilis osteomyelitis complicating bone infarcts in sickle cell disease. Skeletal Radiol 1988; 17: 510-3.
22. Carre M, Sarlangue J, Baronnet R, Nicolau A, Demarquez JL. [Cerebral abscess caused by Proteus mirabilis in the neonatal period.] Arch Fr Pediatr 1987; 44: 871-4. (Article in French)
23. Francois A, Berterottiere D, Aigrain Y, Tachet F, Ropert JC. [Neonatal Proteus mirabilis adrenal gland abscess]. Arch Fr Pediatr 1991; 48: 559-61. (Article in French)
24. Kerns SR, Dougherty K, Pope TL, Scheld WM. Septic sacroiliitis due to Proteus mirabilis. South Med J 1990; 83: 589-91.
25. Ojeda-Vargas M, Pacheco A, Elia M, Villaverde R, Baquero F. Proteus mirabilis as a cause of recurrent lung infection in a cystic fibrosis patient. Eur J Clin Microbiol Infect Dis 1990; 9: 234-5.
26. Krajden S, Kuksa M, Petrea C, Crisp LJ, Penner JL. Expanded clinical spectrum of infections caused by Proteus penneri. J Clin Microbiol 1987; 25: 578-9.
27. Latuszynski DK, Schoch P, Qadir MT, Cunha BA. Proteus penneri urosepsis in a patient with diabetes mellitus. Heart Lung 1998; 27: 146-8.
28. Engler HD, Troy K, Bottone EJ. Bacteremia and subcutaneous abscess caused by Proteus penneri in a neutropenic host. J Clin Microbiol 1990; 28: 1645-6.
29. Christophersen I, Galiana A, Lopez L, Gonzalez S, Bazet C, Padreira W. [Nosocomial outbreak of Proteus penneri infections at a general hospital]. Enferm Infecc Microbiol Clin 1989; 7: 340-1. (Article in Spanish)
30. Jarlier V, Fosse T, Philippon A, and the ICU study group. Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Med 1996; 22: 1057-65.
31. Liu PYF, Gur D, Hall LMC, Livermore DM. Survey of the prevalence of β-lactamases amongst 1000 Gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother 1992; 30: 429-47.
32. Mutnick AH, Turner P J, Jones RN. Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC program (1997-2001). Meropenem Yeraly Susceptibility Test Information Collection. J Chemother 2002; 14: 253-8.
33. Chanal C, Bonnet R, De Champs C, Sirot D, Labia R, Sirot J. Prevalence of β-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital. Antimicrob Agents Chemother 2000; 44: 1930-5.
34. Stock I, Wiedemann B. [Natural antibiotic susceptibility of Proteus species of the Proteus vulgaris complex]. Chemother J 1997; 6: 76-84. (Article in German)
35. Stock I, Wiedemann B. [Determination of natural antibiotic susceptibility]. Chemother J 1998; 7: 127-35. (Article in German)
36. Stock I, Wiedemann B. Natural antibiotic susceptibility of Providencia stuartii, P. rettgeri, P. alcalifaciens and P. rustigianii strains. J Med Microbiol 1998; 47: 629-42.
37. Deutsches Institut für Normung e.V. DIN document 58940-4, Table 1. Susceptibility testing of pathogens to antimicrobial agents, part 4: Evaluation classes of the minimum inhibitory concentration, Supplement 1: MIC break-points of antibacterial agents. Deutsches Institut für Normung e.V. 2000, Berlin, Germany.
38. Comité de l'Antibiogramme de la Société Française de Microbiologie. Statement. Pathol Biol 1998; 46: I-XVI.
39. Olsson-Liljequist B, Larson P, Walder M, Miörner H. Antimicrobial susceptibility testing in Sweden. Part 3: methodology for susceptibility testing. Scand J Infect Dis 1997; 105 (Suppl): 13-23.
40. National Committee for Clinical Laboratory Standards. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards. 2000, Villanova, Pa.
41. Troxler R, von Graevenitz A, Funke G, Wiedemann B, Stock I. Natural antibiotic susceptibility of Listeria species: L. grayi, L. innocua, L. ivanovii, L. monocytogenes, L. seeligeri and L. welshimeri strains. Clin Microbiol Infect 2000; 6: 525-35.
42. Stock I, Heisig P, Wiedemann B. Expression of β-lactamases in Yersinia enterocolitica strains of biovars 2, 4 and 5. J Med Microbiol 1999; 48: 1023-7.
43. Reger PJ, Mockler DF, Miller MA. Comparison of antimicrobial susceptibility, β-lactamase production, plasmid analysis and serum bactericidal activity in Edwardsiella tarda, E. ictaluri and E. hoshinae. J Med Microbiol 1993; 39: 273-81.
44. Stock I, Wiedemann B. Natural antibiotic susceptibilities of Edwardsiella tarda, E. ictaluri, and E. hoshinae. Antimicrob Agents Chemother 2001; 45: 2245-55.
45. Na'was TE, Mawajdeh S, Dababneh A, al-Omari A. In vitro activities of antimicrobial agents against Proteus species from clinical specimens. Br J Biomed Sci 1994; 51: 95-9.
46. Magalhães VD, Schuman W, Castilho BA. A new tetracycline resistance determinant cloned from Proteus mirabilis. Biochim Biophys Acta 1998; 1443: 262-6.
47. Lukomski S, Pytlos M, Serwecinska L, Sidorczyk Z, Jaworski A. Analysis of antibiotic resistance determinants in Proteus penneri. Eur J Clin Microbiol Infect Dis 1993; 12: 467-9.
48. Tsai WC, Chow SF. [Urinary tract infections and microbiological characteristics of Proteus penneri isolated in Taiwan] Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1987; 20: 132-9. (Article in Chinese)
49. Charles IG, Harford S, Brookfield JFY, Shaw WV. Resistance to chloramphenicol in Proteus mirabilis by expression of a chromosomal gene for chloramphenicol acetyltransferase. J Bacteriol 1985; 164: 114-22.
50. Alon U, Davidai G, Berant M, Merzbach D. Five-year survey of changing patterns of susceptibility of bacterial uropathogens to trimethoprim-sulfamethoxazole and other antimicrobial agents. Antimicrob Agents Chemother 1987; 31: 126-8.
51. Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001; 18: 211-5.
52. Bret L, Chanal-Claris C, Sirot D, Chaibi EB, Labia R, Sirot J. Chromosomally encoded AmpC β-lactamase in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother 1998; 42: 1110-4.
53. Pagani L, Migliavacca R, Pallecchi L, Matti C, Giacobone E, Amicosante G, Romero E, Rossolini GM. Emerging extended-spectrum β-lactamases in Proteus mirabilis. J Clin Microbiol 2002; 40: 1549-52.
54. Livermore DM, Williams JD. β-lactams: Mode of action and mechanisms of bacterial resistance. In Lorian V, editor. Antibiotics in laboratory medicine. Baltimore, Maryland, 1996: 502-78.
55. Stock I, Wiedemann B. [Natural antibiotic susceptibility of Yersinia pseudotuberculosis strains]. Chemother J 1999; 8: 219-26. (Article in German)
56. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
57. Aspiotis A, Cullmann W, Dick W, Stieglitz M. Inducible β-lactamases are principally responsible for the naturally occurring resistance towards β-lactam antibiotics in Proteus vulgaris. Chemotherapy 1996; 32: 236-46.
58. Kotelko K. Proteus mirabilis: taxonomic position, peculiarities of growth, components of the cell envelope. Curr Top Microbiol Immunol 1986; 129: 181-215.
59. Sakurai Y, Tsukamoto K, Sawai T. Nucleotide sequence and characterization of a carbenicillin-hydrolyzing penicillinase gene from Proteus mirabilis. J Bacteriol 1991; 173: 7038-41.
60. Bonnet R, Marchandin H, Chanal C, Sirot D, Labia R, De Champs C, Jumas-Bilak E, Sirot J. Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis. Antimicrob Agents Chemother 2002; 46: 2004-6.
61. Grace ME, Gregory FJ, Hung PP, Fu KP. Purification and properties of a β-lactamase from Proteus penneri. J Antibiot 1986; 39: 938-42.
62. Miro E, Barthélémy M, Péduzzi J, Reynaud A, Morand A, Prats G, Labia R. [Properties of a cephalosporinase produced by Proteus penneri inhibited by clavulanic acid]. Pathol Biol (Paris) 1994; 42: 487-90. (Article in French)
63. Datz M, Joris B, Azab EA, Galleni M, Van Beeumen J, Frere JM, Martin HH. A common system controls the induction of very different genes. The class-A beta-lactamase of Proteus oulgaris and the enterobacterial class-C beta-lactamase. Eur J Biochem 1994; 226: 149-57.
64. Ishiguro K, Sugimoto K. Purification and characterization of the Proteus oulgaris BlaA protein, the activator of the beta-lactamase gene. J Biochem 1996; 120: 98-103.
65. Liassine N, Madec S, Ninet B, Metral C, Fouchereau-Peron M, Labia R, Auckenthaler R. Postneurosurgical meningitis due to Proteus penneri with selection of a ceftriaxone-resistant isolate: analysis of chromosomal class A beta-lactamase HugA and its LysR-type regulatory protein HugR. Antimicrob Agents Chemother 2002; 46: 216-9.
66. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53: 637-56.
67. Stock I, Falsen E, Wiedemann B. Moellerella wisconsensis: identification, natural antibiotic suscepti-bility and its dependency on the medium applied. Diagn Microbiol Infect Dis 2002; 45: 1-11.
68. Stock I, Grüger T, Wiedemann B. Natural antibiotic susceptibility of strains of the Enterobacter cloacae complex. Int J Antimicrob Agents 2001; 18: 537-45.
69. Stock I, Wiedemann B. Natural antibiotic susceptibility of Enterobacter amnigenus, E. cancerogenus, E. gergoviae and E. sakazakii strains. Clin Microbiol Infect 2002; 8: 564-78.
70. Stock I. Natural antibiotic susceptibility of Enterobacter spp., with special reference to E. aerogenes and E. intermedius strains. J Chemother 2002; 14, 5: 444-60.
71. Kresken M, Hafner D, and the study group 'Resistance' of the Paul Ehrlich Society for Chemotherapie e.V. [Resistenzsituation bei klinisch wichtigen Infektionserregern gegengber Chemotherapeutika in Mitteleuropa.] Chemother J 2000; 9: 51-86. (Article in German)